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E-mail: gilbert.fruhwirth@kcl.ac.ukRegulatory T cells (Tregs) are emerging as a new cell-based
therapy in solid organ transplantation. Adoptive transfer of
Tregs has been shown preclinically to protect from graft rejec-
tion, and the safety of Treg therapy has been demonstrated in
clinical trials. Despite these successes, the in vivo distribution
and persistence of adoptively transferred Tregs remained
elusive, which hampers clinical translation. Here we isolated
human Tregs using a GMP-compatible protocol and lentivir-
ally transduced them with the human sodium iodide symporter
to render them traceable in vivo by radionuclide imaging.
Engineered human Tregs were characterized for phenotype,
survival, suppressive capacity, and reporter function. To
study their trafficking behavior, they were subsequently admin-
istered to humanized mice with human skin transplants.
Traceable Tregs were quantified in skin grafts by non-invasive
nano-single-photon emission computed tomography (nano-
SPECT)/computed tomography (CT) for up to 40 days, and
the results were validated ex vivo. Using this approach, we
demonstrated that Treg trafficking to skin grafts was regulated
by the presence of recipient Gr-1+ innate immune cells.
We demonstrated the utility of radionuclide reporter gene-
afforded quantitative Treg in vivo tracking, addressing a funda-
mental need in Treg therapy development and offering a
clinically compatible methodology for future Treg therapy
imaging in humans.
INTRODUCTION
Regulatory T cells (Tregs) are immunosuppressive cells with a
fundamental role in maintenance of tolerance to self-antigen
in vivo.1,2 Tregs are characterized by constitutively high expression
of CD25 and the master transcription factor forkhead-box protein
3 (FOXP3). Mice deficient in Foxp3 exhibit systemic autoimmune
disease, and their Tregs have an impaired suppressive capacity
in vitro.324 Molecular Therapy: Methods & Clinical Development Vol. 20 March
This is an open access article under the CC BY license (http://creatiIn transplantation, graft rejection is a detrimental process driven by
alloreactive T cells that recognize donor major histocompatibility
complex (MHC) antigens (alloantigens) via various pathways.3 In
addition to maintaining tolerance to self-antigens, Tregs contribute
to controlling responses to alloantigens, and a correlation between
the proportion of Tregs within a transplanted organ (allograft) and
graft survival has been observed.4–6 This has led to the pursuit of pro-
tocols designed to tip the balance between Tregs and effector T cells
(Teffs) in favor of Tregs to induce transplantation tolerance. One
strategy to increase Treg numbers is purification of Tregs from allo-
graft recipients, expanding and potentially manipulating them in vitro
before re-administration. In immunodeficient mice transplanted with
human skin and reconstituted with peripheral blood mononuclear
cells (PBMCs), adoptive transfer of human in-vitro-expanded poly-
clonal Tregs significantly prolonged the survival of skin allografts.7,8
Polyclonal Treg-based cell therapy approaches yielded early prom-
ising results for prevention of graft versus host disease (GvHD), after
allogeneic hematopoietic stem cell transplantation9,10, and for main-
tenance of C-peptide levels in type I diabetes.11,12 We led two clinical
phase I/II trials using adoptive transfer of polyclonal expanded Tregs
to promote tolerance in kidney (ONE Study, NCT02129881) and liver
(ThRIL, NCT02166177) transplant recipients.13–15 The resultant data2021 ª 2021 The Authors.
vecommons.org/licenses/by/4.0/).
www.moleculartherapy.orgsuggested Treg therapy to be safe and well tolerated and showed some
signs of efficacy.
Despite an increase in the numbers of clinical trials using human
Treg therapy, important questions pertaining to their in vivo fate, dis-
tribution, and location of their function remain unclear. Recently,
polyclonal Tregs labeled with [6,6-2H2]glucose were detected in the
circulation of individuals with type I diabetes for up to one year.12
However, it remains a challenge to identify adoptively transferred
Tregs in tissues non-invasively.
Non-invasive radionuclide imaging by single-photon emission
computed tomography (SPECT) or positron emission tomography
(PET) offers excellent sensitivity with absolute quantification and
true 3D information while being translatable to the clinic. Cell
labeling approaches can be direct or indirect, with each approach
offering distinct advantages and disadvantages.16 We showed pre-
viously that direct radiolabeling of murine CD4+ T cells, with
99mTc-hexamethylpropyleneamine oxime, did not affect cell
viability, but the radiolabeled cells could only be tracked for up
to 24 h because of the short radioisotope half-life of 99mTc
(6 h).17 This enabled assessment of Treg biodistribution within a
day after administration but precluded the desired long-term
tracking of Tregs, which would require longer half-life radioiso-
topes. Longer half-life radioisotopes are available (e.g. 111In and
89Zr) but also elicit a higher radioactive dose,18 limiting the study
length. Using various T lymphocytes, recent studies involved
tracking of about one week but not longer.19–21 In the context of
transplant immunology, aiming to track Tregs to transplants,
one week is a short observation time, and significantly longer
cell tracking would be beneficial.
Long-term cell tracking can be achieved through indirect cell label-
ing, which involves genetic engineering to express a reporter and
render the cells in vivo traceable by repeat imaging.16,22 Treg in vivo
dynamics were assessed using bioluminescence approaches.23–25
However, bioluminescence imaging is not translatable to the clinic
because of the non-human nature of luciferases, which also require
luminogenic substrate administration, and the added disadvantages
of optical imaging at depth (absorption, scatter) precluding reliable
quantification. Radionuclide reporter genes are an alternative that
enables 3D tomographic imaging, and they have also been shown
to be clinically translatable.26 Host reporter genes are from the
same species as cell tracking should occur in and should be endog-
enously expressed in only a very limited number of host tissues to
ensure favorable contrast and overcome any immunogenicity issues
intrinsic to foreign reporters.16,22 One of the most promising host
reporter genes is the human sodium iodide symporter (NIS), which
has been shown to be well tolerated in different cell types, including
cancer cells, cardiomyocytes, stem cells, and T cells.27–30 In a proof-
of-principle study employing retroviral transduction methodology,
we demonstrated ex vivo engineering of murine Tregs to express
NIS and detected the cells in vivo 24 h after administration by
SPECT imaging.31 Importantly, it has also been shown recentlyMolecularthat the radioactivity levels that can be expected to be taken up
into T cells through NIS use during imaging did not cause lasting
DNA damage in T cells.32 Moreover, the matching radiotracers
required for NIS imaging have already been translated to humans
(for thyroid imaging).33,34 These features make NIS a well-estab-
lished reporter gene suitable for preclinical long-term cell tracking
and a candidate reporter for the clinical setting. Notably, so far,
long-term in vivo tracking of human Tregs has not been addressed
using a reporter gene imaging approach that can be translated to the
clinic.
Our goal was to genetically engineer GMP-isolated and in-vitro-
expanded human Tregs, characterize the resultant traceable Tregs,
and apply them to investigate their capacity to home to and reside
within human skin transplants in a humanized mouse model.
Because it has been reported that, during inflammation, soluble me-
diators (for example, chemokines produced by infiltrating granulo-
cytes and monocytes) are critical for recruitment of adaptive
immune cells to antigen-rich tissues,35 we applied our approach
to investigate whether innate immune cells had an effect on Treg
trafficking to skin grafts.
RESULTS
Generation of in-vivo-traceable Tregs
CD4+CD25high Tregs from donor blood were enriched using GMP
protocols13–15 and stimulated with anti-CD3/CD28 beads in the pres-
ence of rapamycin and interleukin-2 (IL-2) (Figure S1). Three days
after stimulation, Tregs were transduced with lentiviral particles
transferring DNA encoding the radionuclide-fluorescence fusion re-
porter gene NIS-GFP (Figure 1A; monomeric GFP aides traceable
Treg generation, purification, and ex vivo detection27,28,36). Trans-
duced NIS-GFP+ Tregs were purified by cell sorting (purity > 99%;
Figure 1B), and NIS-GFP was found predominantly in the plasma
membrane, suggesting correct intracellular reporter trafficking
(Figure 1C). No significant changes in reporter expression levels
were observed over six weeks, suggesting stable NIS-GFP expression
(Figure 1D). Importantly, we also did not find differences in Treg
expansion between untransduced and reporter-expressing Tregs (Fig-
ure 1E). NIS-GFP+ Tregs showed uptake of the radioactive NIS sub-
strate [99mTcO4
] whereas untransduced Tregs did not (Figure 1F).
[99mTc]TcO4
 uptake was also reduced significantly in NIS-GFP+
Tregs in the presence of excess amounts of the NIS co-substrate
perchlorate, demonstrating radiotracer uptake to be specific for
NIS-GFP expression (Figure 1F).
NIS-GFP+ Tregs maintain phenotype and function
To investigate whether reporter transduction and radiolabeling
affect the Treg phenotype, we compared NIS-GFP+ Tregs with un-
transduced Tregs employing established Treg markers (CD25,
FOXP3, and CTLA-4). This comparison was performed with iden-
tical Treg batches that had been exposed to [99mTc]TcO4
 radio-
tracer or vehicle, and no significant effect of NIS transduction and
NIS use (radiolabeling) was detected (Figures 2A and 2B; Figure S2).
Next we assessed the suppressive capacity of NIS-GFP+ TregsTherapy: Methods & Clinical Development Vol. 20 March 2021 325
Figure 1. Generation of Tregs stably expressingNIS-
GFP
(A) Sketch of the lentiviral construct. SFFV, spleen focus-
forming virus promoter. (B) Representative example of
Treg transduction with the NIS-GFP reporter. Post-
transduction FACS yielded more than 99% pure
NIS-GFP+ Tregs. (C) Fluorescence microscopy revealed
NIS-GFP expression in Tregs to be predominantly mem-
branous. Scale bars, 10 mm and 5 mm (inset). (D) Flow
cytometry analysis of NIS-GFP+ Tregs in the weeks after
transduction alongside corresponding untransduced
Tregs (numbers indicate mean fluorescence intensity
[MFI]). One representative of three experiments is shown.
(E) Transduced NIS-FP+ Tregs were sorted by FACS (cf.
B) and expanded further for subsequent experiments over
a period of ten days. Fold expansion of these cells during
this period was quantified and compared with corre-
sponding untransduced parental Tregs. Shown is a box-
and-whisker plot with median and 25th–75th percentiles
indicated as well as min and max values drawn as whis-
kers; n = 9. There was no significant difference between
the cell types. (F) NIS-GFP function as quantified per
[99mTc]TcO4
 uptake in untransduced and NIS-GFP+
Tregs (gray). NaClO4 block reports NIS specificity (black).
n = 3, error bars indicate SD; ANOVA with Tukey multiple
comparisons correction.
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press the proliferation of dye-labeled Teffs. No significant differ-
ences between NIS-GFP+ Tregs and untransduced Tregs were
found, neither in the presence nor in the absence of exposure to
the NIS radiotracer [99mTc]TcO4
 at different Teff:Treg ratios (Fig-
ure 2C; Figure S3). Importantly, these data demonstrated that (1)
NIS-GFP+ Tregs maintained their suppressive function after lentivi-
ral transduction and upon stable reporter expression, and (2) the
amount of [99mTc]TcO4
 used, which is comparable to what NIS-
GFP+ Tregs would experience upon reporter gene imaging in vivo,
did also not impair their function.
These data showed that humanTregs genetically engineered via lentivi-
ral transduction technology to stably express the radionuclide-fluores-
cence reporter NIS-GFP maintained their phenotype and suppressive
function following labeling.
In vivo detection of NIS-GFP+ Tregs in a humanized mouse
model
First we assessed the detection sensitivity of [99mTc]TcO4
-labeled
NIS-GFP+ Tregs in our nanoSPECT/computed tomography (CT)
instrument and found a limit of detection (LOD) of 10,000
NIS-GFP+ Tregs per million untransduced cells (Figure S4). These
data demonstrated the feasibility of Treg tracking by NIS reporter
gene imaging.
Next we determined the traceability of NIS-GFP+ Tregs in vivo in a
well-established human skin xenograft transplant model. Previ-
ously, we had demonstrated the efficacy of human polyclonal
Tregs to reduce alloimmune human skin injury (30 days after326 Molecular Therapy: Methods & Clinical Development Vol. 20 Marchadministration).7,12 Therefore, human skin grafts were prepared
using immunocompromised BALB/c recombination activating
gene 2/gc/ (BRG) mice as recipients. Six to seven weeks after
skin engraftment, transplant-bearing mice were randomized, and
allogeneic CD25-depleted PBMCs were administered intrave-
nously alone or together with NIS-GFP+ Tregs. Importantly,
murine granulocyte receptor 1 (Gr-1)-positive cells, including neu-
trophils and certain monocytes, were still functional in BRG mice.
To achieve a higher level of immunocompromise, Gr-1+ cells were
depleted using an antibody raised against Gr-1 as described previ-
ously (Figure 3A).7,12,38 It is noteworthy that despite this being an
established approach to deplete the remaining Gr-1+ cell using the
indicated antibody, we confirmed its success by histology (Fig-
ure S5). Treg in vivo detection was based on visualization of
NIS-GFP+ Tregs by SPECT imaging with the NIS radiotracer
[99mTc]TcO4
. Notably, the host reporter gene human NIS is
homologous to murine NIS (mNIS), and the radiotracer detected
both forms.37 This explained why we observed, in mice that did
not receive NIS-GFP+ Tregs (Figure 3C), the following signals
attributed to endogenously expressed mNIS: thyroid, salivary,
and lachrymal glands; the stomach; and, at lower levels, the small
intestine and the testes of male mice. Bladder signals were caused
by the expected renal radiotracer excretion. Importantly, in ani-
mals that had received NIS-GFP+ Tregs, we detected the traceable
therapeutic cells in the transplants (Figure 3D). Importantly, none
of the aforementioned organs with endogenous mNIS expression
or involved in renal radiotracer excretion contributed to any back-
ground signals in human skin grafts (cf. Figures 3C and 3D,
insets), enabling quantification of NIS-GFP+ Tregs in the skin
grafts.2021
Figure 2. Assessment of marker expression and suppressive function
(A and B) The Treg markers CD25, FOXP3, and CTLA-4 were quantified by flow
cytometry alongside CD4 (all via antibody staining) and NIS-GFP (via intrinsic GFP
fluorescence). NIS-GFP+ Tregs were analyzed by flow cytometry before and
six days after [99mTc]TcO4
 uptake. Cumulative data describe (A) the percentage
and (B) the mean fluorescence intensities. n = 3, error bars indicate SD, Student’s
t-test with Holm-Sidak multiple comparisons correction for both (A) and (B). For
representative individual data, see Figure S3. (C) Comparison of suppressive ca-
pacity of untransduced and NIS-GFP+ Tregs with or without radiotracer treatment.
Shown are cumulative data of three different Treg batches (donors); error bars
indicate SD. There were no significant differences between cells with or without
radiotracer treatment (Student’s t-test; untransduced Tregs: p1:1 = 0.3739; p1:3 =
0.2508; p1:10 = 0.3139; NIS-GFP
+ Tregs: p1:1 = 0.3739; p1:3 = 0.1012; p1:10 =
0.1194). For representative individual data, see Figure S3.
Figure 3. In vivo detection of NIS-GFP+ Tregs in human skin grafts
(A) Experimental scheme, including imaging conditions (radiotracer and time be-
tween its administration and SPECT imaging). (B) Representative example of a
human skin transplant atop the spine of a BRG mouse on the day of adoptive im-
mune cell transfer. All animals in this experiment (n = 3 in each group) received the
same human skin and Tregs from the same donor; all mice were depleted of Gr-1+
innate immune cells. (C and D) Sagittal sections of SPECT/CT images from repre-
sentative animals that received 5  106 CD25-depleted PBMCs but (C) no NIS-
GFP+ Tregs or (D) 5  106 NIS-GFP+ Tregs 30 days prior to imaging. Overlays of
SPECT images in hue (and on the same scale) with co-registered CT images
(grayscale) are shown. Purple frames indicate magnified areas in different planes,
with the human skin graft circumscribed by dark yellow dotted lines; thin red
crosshair lines indicate how the indicated sections connect to one another.
Endogenous (murine) mNIS expressing organs are visible in both groups and
include thyroid/salivary glands (T/S), stomach (S), and small intestine (Int),37
whereas bladder (Bl) signals are caused by radiotracer excretion. Images demon-
strate (C) that the transplant area atop the spine remained free of any SPECT signals
when no NIS-GFP+ Tregs were administered and (D) that administered NIS-GFP+
Tregs were detected by SPECT imaging at the skin graft as they trafficked to this site
over time.
www.moleculartherapy.orgSerial in vivo imaging revealed a role of Gr-1+ innate immune
cells in Treg recruitment
Next we used serial SPECT/CT imaging to track NIS-GFP+ Tregs at
different time points after intravenous administration into trans-
plant-bearing immunocompromised mice lacking Gr-1+ innate im-
mune cells. BRG mice received traceable NIS-GFP+ Tregs and were
treated with the anti-Gr-1 antibody to deplete this cell compartment
(Figure S5). We found that radiotracer uptake levels in their human
skin grafts did not significantly differ from control animals (no
NIS-GFP+ Tregs and only CD25-depleted PBMCs administered)
for the first 2 weeks (cf. pink versus black lines in Figure 4). Notably,
NIS-GFP+ Treg presence was elevated significantly compared with
control animals at late time points, ranging 30–40 days after admin-
istration (Figure 4). Using non-obese diabetic (NOD).Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) mice, which have less and mostly dysfunctionalMolecularinnate immune cells39 and thus did not receive the anti-Gr-1 anti-
body, we obtained similar results compared with those obtained in
BRG mice with Gr-1+ cell depletion (Figure S6).
Next, to investigate the role of Gr-1+ innate cells on Treg recruitment
to skin grafts, we determined the in vivo trafficking behavior of intra-
venously (i.v.) administered NIS-GFP+ Tregs in transplant-bearing
BRG mice without anti-Gr-1 antibody administration (Figure 4; Fig-
ure S5). Interestingly, NIS-GFP+ Tregs were detectable at the skinTherapy: Methods & Clinical Development Vol. 20 March 2021 327
Figure 4. In vivo tracking of NIS-GFP+ Treg arrival at human skin grafts
(A) Experimental scheme. Purple, human skin graft; green syringe, 5  106 NIS-
GFP+ Tregs; black syringe, 5  106 PBMCs. Cohorts were randomized upon
adoptive cell transfer. (B and C) Longitudinal SPECT/CT images of transplant-
bearing animals at the indicated time points after adoptive cell transfer. Images were
acquired 40 min after [99mTc]TcO4
 administration (20 MBq). Side-view maximum
intensity projections (top row) and coronal sections through the graft (bottom row)
are shown; all images are on the same scale. Radioactive signals above background
in grafts indicate NIS-GFP+ Treg presence. Shown are representative images from
the same animal. (D) Cumulative quantitative analysis of in vivo imaging data. SUV,
standard uptake value. Black dashed/dotted lines represent mean ± SD of pooled
control animals (PBMCs/no Tregs and no adoptive transfer; n = 5). Shown are
cumulative data of all experiments in (B) and (C); n = (7;7;7;5 for (B)) and (6;4;5;4 for
(C)) for the time points day (3;8;15; range [30–40]), respectively. Error bars represent
SD. Multiple t-tests with Holm-Sidak correction for multiple comparisons were used
for statistical analysis and p-values are shown if < 0.05.
Molecular Therapy: Methods & Clinical Developmentgrafts as early as 3 days after administration. Their signals peaked at
around 8 days and remained detectable in the transplants up to
40 days after administration (Figure 4C). Image quantification re-
vealed significant differences between BRG mice without and with
Gr-1+ cell depletion at early time points after Treg administration328 Molecular Therapy: Methods & Clinical Development Vol. 20 March(Figure 4D). Early trafficking of Tregs to the skin in the presence of
Gr-1+ cells suggested an active role of these cells in influencing
Treg recruitment to the graft.
Ex vivo validation of in vivo imaging
Animals of each cohort were sacrificed at the indicated time points,
and radioactivity in the graft tissues was quantified (by g- counting).
Human skin grafts were compared with mouse skin from the same
animal using paired analyses. In control animals that did not receive
traceable Tregs, no significant differences in tissue radioactivity be-
tween human grafts and mouse skins at any time point were observed
(Figure 5A, solid versus dashed black lines), demonstrating no human
graft-specific radiotracer accumulation. In BRG mice that had also
received anti-Gr-1 antibody treatment, we observed no significant
differences between human and mouse tissues for the first 2 weeks
but identified a significant difference between the two skins types
on day 40 (p = 0.0309; Figure 5A, compare solid versus dashed
pink lines). Importantly, in BRG mice with Gr-1+ cells present, the
radioactivity found in human skin grafts was higher than in mouse
skin at all time points (p = 0.0016; Figure 5A, solid versus dashed
blue lines). These comparisons of human skin grafts with mouse
skin from the same animals clearly demonstrated a preference for
traceable human Tregs to accumulate at human skin grafts.
Human skin grafts from different animal cohorts were compared us-
ing unpaired statistical analysis. The radioactivity levels in human
skin grafts on day 8 were significantly higher in BRG mice with
Gr-1+ cells present compared with BRG mice lacking Gr-1+ cells
and control cohorts (Figure 5A). Notably, there were no differences
between mouse skins of the same three animal cohorts. On day 40,
the situation had changed, with both experimental cohorts (BRG
with Gr-1+ cells and BRG without Gr-1+ cells) showing significantly
elevated radioactivity in human skin grafts compared with control an-
imals (p = 0.0340 and p = 0.0071, respectively; Figure 5A; ANOVA
with Holm-Sidak multiple comparison correction). These data
further confirmed our in vivo imaging data.
Moreover, we used immunofluorescence histology to independently
validate the NIS-GFP+ Treg presence in human skin grafts. First, in
control animals that had received only CD25-depleted human
PBMCs, we found human CD3+ (Figure 5B), whereas in additional
control mice that had only received saline, we did not observe the
presence of any human CD3+ cells (Figure 5C). In BRG mice
that were treated with the anti-Gr-1 antibody, we detected human
CD3+FOXP3+ Tregs alongside human CD3+ in the skin grafts on
day 40 (Figure 5D). Importantly, we also found human CD3+FOXP3+
Tregs in the human skin grafts of BRG mice with Gr-1+ cells present
on day 8 and day 40 (Figures 5E and 5F), again confirming our pre-
vious results. We also obtained ex vivo results in line with in vivo im-
aging data for NSG mice (Figures S5D and S5E).
In summary, our in vivo imaging data were confirmed by two inde-
pendent ex vivo tissue analyses and demonstrated murine Gr-1+ cells
to affect human Treg arrival in human skin graft models.2021
Figure 5. Ex vivo tissue analysis of transplanted tissues
(A) Ex vivo radioactivity analysis of harvested tissues. Mouse skin was harvested
from a region above the lower spine. Human skin grafts were compared with mouse
skin from the same animal using paired t-tests. No Treg/PBMC-only control: not
significant over all time points (p = 0.2526), solid versus dashed black lines; BRG
without Gr-1+ cells: not significant for early time points (p = 0.4850) but significant on
day 40 (p = 0.0309), solid versus dashed pink lines; BRG with Gr-1+ cells present:
significant over all time points (p = 0.0016), solid versus dashed blue lines. Human
skin grafts from different animal cohorts were compared using unpaired ANOVA on
day 8 or day 40, with p values shown in (A). Cumulative data; n = 2 (days 3 and 15)
and n = 4 (days 8 and 40); error bars indicate SEM. (B–E) Immunofluorescence
staining of harvested tissues with anti-human CD3 (red in merged images) and anti-
FOXP3 antibodies (green in merged images). Indicated times refer to days after
adoptive Treg transfer as in Figure 4. Shown are (B) untreated mice that received
only PBMCs or (C) no cells (saline only). (D) Representative confocal micrographs of
www.moleculartherapy.org
MolecularHuman Treg migration is enhanced by murine neutrophils/
monocytes in vitro
To gain more mechanistic insights into the role of innate immune
cells on Treg recruitment, we tested whether murine neutrophils
and/or monocytes could affect human Treg migration using in vitro
transmigration assays.
First we analyzed whether human Tregs responded to the murine
chemokines CCL17/CCL22. It has been reported previously that
Tregs are responsive to gradients of chemokines engaging
CCR4,40,41 and we confirmed here that human Tregs expanded
in vitro according to our GMP protocol continued to express high
levels of CCR4 (Figure S7). The same human Treg preparations
used for in vivo tracking experiments (see Figure S8A for individual
donors) were seeded into the top well of a Transwell system, and their
migration through a 3 mm porous membrane was quantified, with the
bottom chamber containing medium with the indicated admixtures.
Under some conditions, Tregs were pre-treated with pertussis toxin
(PTX). The murine chemokines CCL17/CCL22 were able to increase
human Treg migration (p < 0.0001, two-way ANOVA), an effect that
was reversed by PTX pre-treatment of Tregs (Figures 6A and 6B),
suggesting G-protein-coupled receptor (GPCR) involvement.
Having established that human Tregs responded to murine pro-
migratory stimuli, we then investigated whether isolated murine
neutrophils and/or monocytes (Figures S8B and S8C) could induce
human Treg migration. To exclude any direct cell-cell interactions,
neutrophils/monocytes were provided in the bottom chambers,
whereas human Tregs were added to the top well of the Transwell
system. Notably, neutrophils and monocytes were activated in this
experiment because of the use of zymosan during their preparation
(Materials and methods). Neutrophils and monocytes as well as
their combination significantly increased human Treg migration
(Figures 6C and 6D; p = 0.0112, two-way ANOVA). A synergistic
effect of neutrophils and monocytes was not observed. Notably,
enhancement of human Treg motility was reduced when they
were pre-treated with PTX, with no significant migration differences
detected between the presence or absence of the indicated cell types
(Figures 6E and 6F; p = 0.2478, two-way ANOVA).
Taken together, murine Gr-1+ cells accelerated human Treg recruit-
ment to inflammatory sites (such as human skin graft models) by pro-
duction of GPCR ligands, likely chemokines, which cross-reacted
with GPCRs on human Tregs.
DISCUSSION
Previously, we have demonstrated the efficacy of human polyclonal
Tregs at reducing alloimmune injury in a human skin xenograftGr-1+ cell-depleted mice, which received PBMCs and NIS-GFP+ Tregs. (E) exper-
iments as in (C) but performed in BRG mice without Gr-1+ cell depletion. CD3
staining is indicative of administered PBMC-derived human T cells and Tregs,
whereas FOXP3 staining identified administered human Tregs only. Scale bars are
100 mm.
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Figure 6. In vitro Treg migration assay
(A) Transwell migration assay (3 mm pore size) of human
Tregs from five different donors (top chamber). The bot-
tom chambers contained growth medium without or with
the chemokines CCL17/CCL22. PTX indicates that Tregs
were pre-treated with pertussis toxin (PTX). (B) Cumulative
data of (A) showing mean ± SD. Two-way ANOVA re-
vealed significant differences (p < 0.0001). Migration
increased significantly with CCL17/CCL22 (p = 0.0001
with Dunnett’s multiple comparisons test) compared with
other conditions. (C) Transwell migration assay as in (A)
but with the bottom chambers containing the following
purified murine cells: none, neutrophils, monocytes, and
neutrophils and monocytes. Data are grouped per donor.
(D) Cumulative data of (C) showing mean ± SD. Two-way
ANOVA revealed significant differences with different cells
admixed (p = 0.0112). Dunnett’s multiple comparisons
test revealed significant differences for each cell admixture
compared with medium only (see p values in the figure). (E
and F) Data from the same experiments as in (C) and (D),
but Tregs were pre-treated with PTX. No significant dif-
ferences were found between the groups by the same
statistical tests as in (C) and (D).
Molecular Therapy: Methods & Clinical Developmenttransplant model.7,8 However, little was known about the in vivo dis-
tribution and fate of administered Tregs, and it remained extremely
challenging to track adoptively transferred Tregs non-invasively in
solid tissues. We previously attempted to assess the in vivo distribu-
tion of murine Tregs by whole-body imaging within a day of admin-
istration.17,31 What remained elusive was long-term tracking as well
as tracking of human Tregs in skin transplant models to quantify their
arrival at transplant sites.
Therefore, we used the well-established dual-mode reporter NIS-
GFP28 to enable long-term in vivo tracking. The Achilles heel of all
reporter gene-afforded cell tracking is the additional regulatory hur-
dle upon clinical translation because of the need to genetically engi-
neer the cell product. However, chimeric antigen receptor (CAR)330 Molecular Therapy: Methods & Clinical Development Vol. 20 March 2021Treg therapy has recently emerged as the next-
generation strategy for Treg therapy. We and
others have already successfully generated and
characterized prototype CAR Tregs for various
indications, including colitis and multiple scle-
rosis and in humanized mouse models of
xeno-GvHD and human skin transplanta-
tion.38,42–44 We performed gene transfer into
Tregs using lentiviral technology, which has
been used successfully for genetic engineering
of cell-based therapeutic agents in the clinic
before (e.g., anti-cancer CAR T cell therapeutic
agents).45,46 The first CAR Treg clinical trial
has been granted by UK Medicines and Health-
care products Regulatory Agency (MHRA)
authorization: a phase I/II clinical trial (STEAD-
FAST) for kidney transplant patients. Therefore,investigation of the suitability of reporter gene technology for thera-
peutic Tregs was worthwhile because it provided another mosaic
piece in the journey to further develop and translate Treg/CAR
Treg therapy for human use.
The most promising host reporters available for our purpose were
NIS37 and prostate-specific membrane antigen47 (for a review of
host reporter genes for immune cell tracking, see Ashmore-Harris
et al.16), neither of which was expressed in human or mouse dermis
or epidermis. NIS offered the local technical advantage of a gener-
ator-produced radiotracer ([99 mTc]TcO4
) for SPECT imaging,
avoiding radiotracer synthesis on each imaging day. Preclinically,
the sensitivity advantages of PET over SPECT are not so pronounced
on high-quality instrumentation; however, clinically, PET is superior
www.moleculartherapy.orgto SPECT in sensitivity. Importantly, a clinical PET tracer for NIS is
already available ([18F]BF4
)28,33 and will be particularly useful in
the future when combined with new total-body PET instrumentation
that has been shown to offer further significant sensitivity
improvements (i.e., 40-fold improvement of total-body PET over ex-
isting clinical PET48). Moreover, NIS has been reported to be very
sensitive to cell viability because of its dependence on the cellular
Na+/K+ gradient,37 enabling reliable imaging of live cells only. The
fluorescent co-reporter GFP in our fusion reporter NIS-GFP helped
streamline generation of traceable cells for preclinical experimenta-
tion.27,28,36 Notably, NIS-fluorescent protein fusion reporters have
been shown previously (1) to be correctly localized to the plasma
membrane and function in several different cell types (rodent and
human cancer cells,20,27–29,36 human CAR T cells,49 and hepato-
cyte-like cells29) and (2) to mediate uptake of various substrates
similarly to unmodified NIS (for similar relative substrate uptake of
NIS substrates, compare Figure S9A, Diocou et al.36, and Khoshnevi-
san et al.50 with Portulano et al.37 and Dohán et al.;51 for comparative
considerations relating to the NIS Michaelis-Menten constant for
tetrahedral substrates, see Figure S9B). Importantly, although NIS-
GFP was practical for preclinical experimentation, removal of GFP
will be required to render our Treg tracking approach fully compat-
ible with the workflows required for human application. Conse-
quently, selection conditions will need to change, but suitable NIS an-
tibodies or alternative selective expansion strategies52 are already
available.
One apparent shortcoming of radionuclide reporter gene imaging ap-
proaches is their limited spatial resolution (lowmillimeter range). This
can be overcome by combining them with technologies that provide
routinely about an order of magnitude higher resolution and anatom-
ical context, such as X-ray CT or magnetic resonance imaging
(MRI).53 Because this generally leads to better interpretability of ob-
tained co-registered images by combining the best of both worlds,
we also adopted a multi-modal SPECT-CT imaging approach
throughout this work.
In this work, we generated Tregs stably expressingNIS-GFP for amin-
imum of 6 weeks (Figure 1); we did not detect any negative effect of
lentiviral transduction on Treg expansion (Figure 1) or on Treg phe-
notypes or suppressive function (Figure 2). Importantly, therewas also
no negative effect of radiolabeling NIS-GFP+ Tregs with the SPECT
radiotracer [99 mTc]TcO4
 followed by full radioactivity decay (Fig-
ure 2), lending credibility to the overall reporter imaging strategy to
be safe for long-termmonitoring of Tregs (in line with previous obser-
vations that it is safe in Teffs32). We found the LOD for NIS-GFP+
Tregs in our instrument to be104 cells/million (Figure S4), roughly
one order of magnitude lower than what we found previously for can-
cer cells;27 we attributed this to the Tregs being about2-fold smaller
in diameter (amounting to1/8 in volume, taking up at least 8-fold less
radiotracer per cell). In this setting, we were able to track NIS-GFP+
Tregs for 40 days after administration, only limited in time by animal
license regulations, and ex vivo data confirmed in vivo results (Figures
4 and 5). Future work will need to focus on more in-depth analysis ofMolecularpotential reporter gene effects and put emphasis on potential tran-
scriptomic, proteomic, and metabolomic changes.
Previous work in mice (for example, in an islet allograft model)
demonstrated that Tregs migrated from the blood stream first to in-
flamed allografts and subsequently to draining lymph nodes.54,55 The
latter phenomenon was not detected in our studies, not because of
limited detection sensitivity but because of the lack of functional
lymph nodes in the immunocompromised mice used in this human-
ized model. Several studies in cancer and pregnancy research have
suggested roles of neutrophils or monocyte-derived suppressor cells
(MDSCs) in induction and recruitment of Tregs to tumors.56–58
Notably, MDSCs were first identified to play an important role in
tolerance induction in a rat kidney transplant model.59 There are
two MDSC subtypes, monocytic (M)-MDSCs and polymorphonu-
clear/granulocytic (PMN/G)-MDSCs, which show some phenotypic
similarity to monocytes or neutrophils, respectively, and both present
with immune-suppressive functions. Furthermore, adoptive transfer
experiments with M-MDSCs and PMN-MDSCs in a heart transplant
model demonstrated a role of these MDSC in Treg expansion in the
transplant and for prolonged allograft survival.60 Despite much
research, not least in human transplantation, where a positive corre-
lation between MDSCs and Tregs has been observed61,62, the detailed
mechanisms by whichMDSCs induce Tregs still remain unclear. Treg
migration to inflamed islet allografts, however, has been found to
depend on CCR2, CCR5, and, importantly, CCR4.54 Neutrophils
and MDSCs produce the chemokines CCL17/CCL22, which are li-
gands for CCR4 (Iellem et al.;40 Figure S7), and expression of this che-
mokine receptor by Tregs has been implicated previously in their
migration to allografts.54 Furthermore, CCL17 has also been shown
to be involved in neutrophil-mediated Treg recruitment to tumors.58
Gr-1+ murine innate immune cells comprise neutrophils and subsets
of monocytes and dendritic cells. A Gr-1+ monocyte subset has been
observed previously in a cardiac transplant model,63 and Gr-1+
monocytes have also been shown to differentiate into tolerogenic den-
dritic cells that produced IL-10 and induced Treg responses in vivo in
tumors.64 We hypothesized that murine Gr-1+ cells might also affect
Treg recruitment in human skin transplant models. In vivo tracking
of NIS-GFP+ Tregs in human skin transplant-bearing BRG mice
that were either left untreated or depleted of Gr-1+ murine cells re-
vealed significant differences in NIS-GFP+ Treg recruitment to the
grafts (Figures 4 and 5). These results were supported by data from
NSG mice (Figure S6), which have reduced amounts of functional
innate immune cells, including Gr-1+ cells,39 and corroborated by
subsequent in vitro assays demonstrating enhanced migration of hu-
man Tregs toward Gr-1+ murine neutrophils and monocytes (Fig-
ure 6B). We further confirmed that human Tregs were responsive
to murine CCL17/CCL22 (Figure 6A), and our results are in line
with previous data.65 Our finding that murine Gr-1+ cell depletion re-
sulted in delayed Treg detection at the human transplant (3–4weeks
of delay; Figures 4 and 5) further suggested a major role of the CCR4-
CCL17/CCL22 axis and warrants future investigations. Although use
of human Tregs in mice could have been a limitation in understand-
ing the migration of human Tregs, our results further demonstratedTherapy: Methods & Clinical Development Vol. 20 March 2021 331
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cells. Notably, the work presented here in the context of transplanta-
tion suggests that, for Tregs that lack antigen specificity, the speed of
migration to the transplant is controlled by the level of inflammation.
In contrast, if Tregs present with donor-specificity, then their speed of
migration is dictated by recognition of the donor antigen on endothe-
lial cells, and they have been shown to migrate to the respective skin
graft within a week, even in the absence of innate immune cells.25,38
This is in agreement with the important role of antigen recognition
on endothelial cells for recruitment of T cells into tissue that has
been reported previously.66 Recently, we extended this observation
to CAR-expressing Tregs in the same humanized mouse model
described in this study. Recognition of human leukocyte antigen
(HLA)-A2 by A2-specific CAR Tregs favored migration of these cells
to human skin.38
The results of our study demonstrate that NIS is a suitable radionu-
clide reporter gene for non-invasive long-term tracking of Tregs.
The Treg therapy field is currently moving toward CAR Tregs, not
least supported by several newly formed companies concerned with
CAR development and optimization specifically for CAR Treg ther-
apy. Importantly, like for anti-cancer CAR T cell therapy intended
to treat tumors, there is also a requirement to monitor (CAR) Treg
distribution and fate in therapy recipients. Here we provide a preclin-
ical proof of principle to support translation of long-term tracking of
(CAR) Tregs for future clinical application. Our methodology is well
suited to support future CAR Treg tracking work because it relies on
genetic engineering, which is a prerequisite for CAR Treg therapy,
and therefore no major additional regulatory burden is added to
enable imaging/monitoring. Further steps on the path to clinical
translation include first convincing others that the added cost of
including imaging in trials is low compared with the production
cost and value of this cell therapy type and second combining CAR
and the NIS reporter into the same final vector for human cell ther-
apy. Besides aspects relating to clinical translation of Treg therapy,
our work provides a strategy to implement quantitative 3D tomo-
graphic imaging into the workflows of preclinical Treg therapy devel-
opment, and, not least, we contribute, with our findings regarding the
role of innate immune cells, to the increasing understanding of hu-
man Treg migration to human skin grafts.
MATERIALS AND METHODS
Information regarding lentivirus production, flow cytometry marker
analysis and fluorescence microscopy of cells, radiotracer uptake into
cells, and determination of detection sensitivity of cells is detailed in
the Supplemental Materials and Methods.
Ethics statement
The study involved human samples as well as animals. All procedures
related to animal work were performed in accordance with all legal,
ethical, and institutional requirements (PPL70/7302). Sample sizes
of in vivo experiments were based on prior work from our labora-
tories27,28,38 and kept to a minimum in line with law and ethical
guidelines for animal research in the United Kingdom, as were the332 Molecular Therapy: Methods & Clinical Development Vol. 20 Marchin vivo endpoints. Human skin and blood were obtained with ethics
approval (institutional review board reference 09/H0707/86). Trans-
plant-bearing animals were randomized before PBMC/Treg
administration.
Reagents
Standard reagents were from Corning, Merck, Sarstedt, Thermo
Fisher Scientific, TPP, or VWR. [99mTc]TcO4
 was generator-eluted
as a sodium salt solution and used within 12 h of elution.
Animals
BRG mice (from A. Hayday, King’s College London) were bred at
licensed in-house animal facilities. NSG and C57BL/6 mice were pur-
chased from Charles River Laboratories UK. All mice used were male
and between 6 and 8 weeks old at the beginning of the experiment.
Mice were maintained within the King’s College London Biological
Services Unit under specific pathogen-free conditions in a dedicated
and licensed air-conditioned animal room (at 23C ± 2C and 40%–
60% relative humidity) under light/dark cycles lasting 12 h every day.
They were kept in individually ventilated standard plastic cages
(IVCs; 501 cm2 floor space, Tecniplast) including environmental
enrichment and beddingmaterial in the form of sterilized wood chips,
paper strips, and one cardboard roll per cage. Maximum cage occu-
pancy was five animals, and animals were moved to fresh cages
with fresh environmental enrichment and bedding material twice
per week. Sterilized tap water and food were available ad libitum;
food was PicoLab Rodent Diet 20 (LabDiet) in the form of 2.5 
1.6  1.0 cm oval pellets that were supplied at the top of the cages.
For imaging, animals were anesthetized using isoflurane (1.5% [v/v]
in pure O2). After imaging, mice were left to recover from anesthesia
(by withdrawal of anesthetic) in a pre-warmed chamber or sacrificed
under anesthesia by cervical dislocation. No adverse events were asso-
ciated with the procedures performed in this study, and animals put
on weight in line with strain expectations (data from Charles River
UK) throughout. Sentinel animals were kept on the same IVC racks
as experimental animals and were confirmed to be healthy after
completion of the studies.
Purification and culture of human PBMCs, Tregs, and Teffs
Cells were isolated from peripheral blood donated by anonymous
healthy volunteers via the National Blood Service with informed con-
sent according to our GMP protocols.13–15 PBMCs were separated by
Lymphoprep density gradient centrifugation (PAA Laboratories).
CD4+ T cells were enriched using RosetteSep (STEMCELL Technol-
ogies), followed by selection and separation of CD4+CD25+ Tregs and
CD4+CD25 Teffs using CD25 microbeads (Miltenyi Biotec).
PBMCs were also depleted of CD25+ cells by using CD25 microbeads
(Miltenyi) and are referred to hereafter as CD25 PBMCs. Aliquots of
CD25 PBMCs, Tregs, and Teffs were cryopreserved in 5% (v/v) hu-
man serum (BioSera) containing 10% (v/v) DMSO. Tregs were acti-
vated with anti-CD3/CD28 beads (1:1 bead:cell ratio, Miltenyi) and
cultured in X-Vivo15 medium (Lonza) supplemented with 5% (v/v)
human AB serum (BioSera; Treg medium) and 100 nM rapamycin
(LC-Laboratories). 1,000 U/mL recombinant human IL-22021
www.moleculartherapy.org(Proleukin-Novartis) was added 72 h after cell isolation. After
10 days, Tregs were activated with anti-CD3/CD28 beads (1:1 bead:-
cell ratio) for further expansion, which was repeated every 10 days for
expansion and longevity. X-Vivo15 medium supplemented with hu-
man IL-2 and rapamycin (see above) was used to feed the cells every
twodays. Tregs were cultured at 37C in the presence of 5% (v/v) CO2
in a humidified incubator.
Generation of NIS-GFP-expressing Tregs
Tregs (3 days after isolation) were transduced with lentiviral particles
transferring NIS-GFP as described previously.28,38 Briefly, tissue cul-
ture plates were coated with 50 mg/mL retronectin (TakaraBio) over-
night at 4C before concentrated lentivirus particles and Tregs were
added. Treg medium contained anti-CD3/CD28 beads, IL-2, and rapa-
mycin. After 72 h, virus-containingmediumwas washed off, and Tregs
weremaintained with fresh Tregmedium every 48 h for seven days un-
til fluorescence-activated cell sorting (FACS; BD FACSAria II, GFP
channel). After sorting, NIS-GFP+ Tregs were re-stimulated in Treg
medium containing anti-CD3/CD28 beads, IL-2, and rapamycin.
Suppression assay
107 cells/mL HLA-A2-mismatched CD4+CD25 Teffs were resus-
pended in staining solution containing 5 mM CellTrace Violet (CT-
V) and incubated at 37C for 15 min prior to co-culture. Tregs and
labeled Teffs were co-cultured in X-Vivo medium at the indicated ra-
tios in the presence of anti-CD3/CD28 beads. Teff proliferation was
assessed after five days by quantifying cellular CT-V using flow cy-
tometry. Results are shown as percent suppression (the inverse of
percent Teff proliferation) relative to Teffs cultured alone.
Transwell migration assay
Female 8- to 10-week-old C57BL/6 mice received 1 mg/mL of
zymosan intraperitoneally (i.p.) and were culled 4 and 18 h later to
obtain neutrophils and monocytes from peritoneal cavities (via PBS
washes), respectively. For monocytes, cells were left for 1 h at 37C
in RPMI medium without serum, allowing monocytes to adhere.
Non-adherent cells were discarded. Cells were harvested, washed
twice in cold PBS, counted, resuspended (RPMI medium containing
2% [v/v] fetal calf serum [FCS]), and 3  105 cells/700 mL were
plated per 24 wells, forming the bottom wells of the migration assay.
Some wells received admixtures of CCL17 and CCL22 (PeproTech,
1 ng/mL each).
Human Tregs were isolated/purified as described above. Prior to
plating, some Tregs were treated for 1 h with 0.1 ng/mL PTX. Tregs
were counted, resuspended at 3  105 Tregs/300mL in Treg medium
and added to the top of the Transwell chambers (3-mmpore size). The
Tregs that migrated to the bottom chamber within 2 h were counted
while discriminating potentially present floating neutrophils or
monocytes based on cell size.
Human skin xenograft transplant model
Human skinwas obtained from routine abdominoplasty with informed
consent and ethical approval (reference 06/Q0704/18). Donor HLA-MolecularA2+ split-thickness skin grafts were transplanted onto 10- to
12-week-old recipient BRG or NSG mice as described previously.7
Briefly, split-thickness (500–700 mm) skin explants were harvested
with a dermatome (Zimmer), and 1.5-cm2 pieces were transplanted
into graft beds on the indicated animals. Human skin grafts were fixed,
epidermal side up, onto similarly sized defects on recipient backs with
an absorbable tissue seal (Vet-Bond, Braun Medical). Grafts were
covered with Fucidin microbicide (Leo Laboratories), secured with
Tegaderm film dressing (3M) for seven days, and skin was allowed to
engraft for 40 days in total before initiation of experiments.
5–6 weeks after skin transplantation, 5  106 PBMCs that were
depleted of CD25+ cells (see above) were then administered i.v.
with or without 5  106 Tregs. No animals developed symptoms of
xenogeneic GvHD, which was confirmed by maintenance of stable
body weight. Skin grafts were subjected to visual and tactile inspection
weekly for evidence of graft injury, and experiments ended 5–6 weeks
after Teff transfer at the latest. As indicated in the experimental
schemes, some BRG mice received 100 mg anti-mouse Gr-1 (RB6-
8C5, Bio X Cell, 1 mg/mL in saline) i.p. every two days (Figure 3A).38
In vivo imaging and image analysis
Micewere anesthetizedwith 2% (v/v) isoflurane/O2. SPECT/CT imag-
ing was performed on animals that had received NIS-GFP+ Tregs. 20
MBq [99mTc]TcO4
 (in 100 mL sterile PBS) was administered i.v. into
anaesthetized animals, and SPECT scans were acquired 40 min later
(NanoScan SPECT/CT from Mediso equipped with high-resolution
multi-pinhole collimators for mouse imaging; 99mTc SPECT resolu-
tion, 0.7 mm; CT resolution, sub-100 mm isotropic voxel). CT (55
kVp tube voltage, 1,200 ms exposure time, 360 projections) was per-
formed after tracer administration but before SPECT. Repeat imaging
with the same radiotracer was not affected by tracer amounts from
prior imaging sessions.36
SPECT/CT data were reconstructed using Tera-Tomo (Mediso) with
corrections for attenuation, detector dead time, and radioisotope
decay in place as needed. All images were analyzed using VivoQuant
software (inviCRO), enabling delineation of regions of interest (ROIs)
for quantification of activity. CT images were used to draw ROIs and
provide the volumes required for standard uptake value calculations.
The total activity in the whole animal (excluding the tail) at the time
of tracer administration was defined as the injected dose (ID).
Ex vivo analyses of tissues
For analysis of radioactivity in harvested tissues, tissues were weighed,
and radioactivity was quantified using a g- counter (1282-Compu-
gamma, LKB-Wallac) together with calibration standards. Data
were expressed as %ID/g.
Skin grafts were harvested alongside normal mouse skin of similar
size (from the lower back) for histology and frozen in Optimal Cut-
ting Temperature (OCT) compound followed by tissue sectioning
(8 mm). Thawed sections were fixed in 4% paraformaldehyde/PBS
for 10 min, permeabilized (0.2% [v/v] Triton X-100/PBS), washed,Therapy: Methods & Clinical Development Vol. 20 March 2021 333
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gelatin and 0.25% [v/v] Tween 20) before being stained with the
following primary antibodies (2 mg/mL) overnight at 4C: anti-hu-
man CD3 (polyclonal rabbit, A0452, Dako), anti-FOXP3 (mono-
clonal rat, clone PCH101, eBioscience), anti-Gr-1 (monoclonal rat,
RB6-8C5, eBioscience), and anti-GFP (monoclonal mouse, 3E6, Invi-
trogen). After washing, sections were stained with secondary anti-
bodies: goat anti-mouse-AlexaFluor 555, anti-rabbit-AlexaFluor 568
(Invitrogen), and anti-rat-Cy5 (Jackson ImmunoResearch). Nuclei
were stained with 4,6-diamidino-2-phenylindole (DAPI; 10 mg/mL
PBS). Samples were mounted using fluorescence mounting medium
(Dako) and imaged on a NikonA1 confocal microscope. Fiji/ImageJ
v.1.5 software was used for analysis.Statistical analysis
Statistical analysis was performed using Prism v.7 software (Graph-
Pad); details are given in the text and figure legends. Generally, the
significance level a was set to 0.05.SUPPLEMENTAL INFORMATION
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